Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + cytarabine
- Development stage
- Unknown
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
Methotrexate + cytarabine is a combination of two chemotherapy agents commonly used in the treatment of various hematological malignancies, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and primary central nervous system lymphoma (PCNSL)[2][5][6]. Methotrexate is an antimetabolite that inhibits enzymes involved in nucleotide synthesis—primarily dihydrofolate reductase—thereby preventing DNA synthesis and cell division[8]. Cytarabine is a nucleoside analog that interferes with DNA synthesis by inhibiting DNA polymerase. The combination exploits their complementary mechanisms to target rapidly dividing cancer cells. Sequential administration (methotrexate followed by cytarabine) has been shown to be synergistic in preclinical studies[6]. Both drugs are widely used as part of multi-agent regimens for hematologic cancers.
- Other names
- MTX + Ara-C
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)CDA (Cytidine deaminase)POLA1 (DNA polymerase alpha)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)PPAT (Amidophosphoribosyltransferase)
Beyond the preview
Go deeper on methotrexate + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + cytarabine.